Advertisement

Topics

Search Results for "New Arthritis Medication 2012"

16:50 EDT 23rd June 2017 | BioPortfolio

Matching Channels

Matching News

Registry study: Lymphoma risk for patients with rheumatoid arthritis remains increased

The risk for malignant lymphoma remained increased for patients with rheumatoid arthritis, according to recently published population-based data for 1997 to 2012. Karin Hellgren, MD, PhD, at the ...

A diagnosis of psoriatic arthritis led Pam Relph from the army to the Paralympics, just in time to win gold (twice)

Pam Relph’s heartbreak when she was medically discharged from the army due to psoriatic arthritis was rapidly followed by elation at finding herself on the British Paralympic rowing team, training f...

Assay opens way to autoantibodies treatment for rheumatoid arthritis

A new discovery, conducted by researchers at the NYU Langone Medical Center and the University of Pittsburgh, has pointed towards a potential shift in the way that rheumatoid arthritis (RA) could be t...

Early intervention in pre-rheumatoid arthritis reduces risk of rheumatoid arthritis

Early therapeutic intervention in people with pre-rheumatoid arthritis significantly reduces the risk of the occurrence of rheumatoid arthritis 52 weeks later, experts highlight at the Annual European...

Psoriatic arthritis was associated with osteoporosis, ankylosing spondylitis

Investigators of this cross-sectional study found psoriasis and psoriatic arthritis correlated with pathologic fractures and other bone-related conditions. Johnathan I. Silverberg , MD...

Rheumatoid Arthritis Drug May Not Ease Chronic Fatigue Syndrome After All

MONDAY, March 6, 2017 -- A small-scale clinical trial has cast doubt upon the potential usefulness of an anti-inflammatory drug to treat chronic fatigue syndrome. Doctors had hoped that anakinra (Kine...

CFDA Approves Pfizer Oral Arthritis Treatment for China Use

Pfizer has received permission from the CFDA to market an oral treatment for rheumatoid arthritis in China. Xeljanz® (tofacitinib citrate), a Janus kinase inhibitor, is indicated for adult patient...

Lilly and Incyte Announce FDA Fails to Approve Baricitinib for Rheumatoid Arthritis

INDIANAPOLIS–(BUSINESS WIRE)–Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete re...

Matching PubMed Articles

Associations Between Patient Characteristics and the Amount of Arthritis Medication Information Patients Receive.

Little is known about factors associated with the receipt of medication information among arthritis patients. This study explores information source receipt and associations between demographic and cl...

Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which results in extensive articular and extra-articular morbidity and increased mortality from cardiovascular disease. Despite an incre...

Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions.

Self-injectable TNF inhibitors are increasingly used early in the chronic treatment of moderate to severe rheumatologic conditions. We estimated medication adherence/persistence over time following in...

Medication Non-Adherence in Systemic Lupus Erythematosus: A Systematic Review.

Medication non-adherence has not been well characterized in systemic lupus erythematosus (SLE). Our objective was to a conduct a systematic review of the literature examining the burden and determinan...

Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.

To evaluate non-adherence to prescribed subcutaneous biologicals in rheumatoid arthritis (RA) patients in Spain.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement